Imatinib Mesylate Tablet, Film Coated
Product Images NDC 68001-490

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 68001-490). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

400mg Label

Label for Imatinib Mesylate Tablets 400 mg by BluePoint Laboratories, presented in a 30-tablet package. The label includes storage instructions, usual dosage note, and manufacturer details: Sun Pharmaceutical Industries Ltd., Gujarat, India. Prominent branding with OncoPoint and barcodes are visible, along with placeholders for GTIN, lot number, expiration date, and serial number.*

FDA Label Image

Imatinib-structure (Imatinib Structure)

Chemical structure of imatinib mesylate, showing its molecular arrangement including aromatic rings, nitrogen atoms, and the methanesulfonic acid (mesylate) group.*

FDA Label Image

100mg Label (Spl Imatinib 100 mg)

Label for Imatinib Mesylate 100 mg film-coated tablets by BluePoint Laboratories, containing 90 tablets. The label includes storage instructions, dosage form, and manufacturer details: Sun Pharmaceutical Industries Ltd., India. Barcode and regulatory identifiers are visible.*

FDA Label Image

Spl-imatinib-fig1 (Spl Imatinib Fig1)

A Kaplan-Meier survival curve chart depicting percent of patients without progression over time in months since randomization for two treatment arms: Imatinib Mesylate and IFN+Ara-C. The chart includes number of patients at progression and censoring, hazard ratio with confidence interval, and statistical significance (P<0.0001). Imatinib Mesylate shows higher progression-free survival compared to IFN+Ara-C throughout the 72-month period.*

FDA Label Image

Spl-imatinib-fig2 (Spl Imatinib Fig2)

A Kaplan-Meier survival curve comparing the percentage without progression to AP or BC over 72 months since randomization for two treatment arms: imatinib mesylate and IFN+Ara-C. The chart includes patient numbers at various follow-up points and hazard ratio with confidence interval, indicating a statistically significant difference favoring imatinib mesylate.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.